{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:06Z","timestamp":1787785566029,"version":"build-2784847793"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000654","name":"Marie Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00051","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T14:58:48Z","timestamp":1580741928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma"],"prefix":"10.3389","volume":"10","author":[{"given":"Soudabeh","family":"Rad Pour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsis A.","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gomez-Cabrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pernemalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Mole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Tegn\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.15586\/codon.cutaneousmelanoma.2017","volume-title":"Cutaneous Melanoma: Etiology and Therapy","author":"Ward","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-017-0320-y","article-title":"Combinatorial therapies in melanoma: MAPK inhibitors and beyond","volume":"19","author":"Zhou","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fonc.2014.00110","article-title":"Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels","volume":"4","author":"Leung","year":"2014","journal-title":"Front Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"O7","DOI":"10.1186\/2051-1426-3-S2-O7","article-title":"Preliminary results from a Phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers","volume":"3","author":"Gangadhar","year":"2015","journal-title":"J Immuno Therapy Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1200\/JCO.2016.34.15_suppl.3075","article-title":"Updates on phase1b\/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma","volume":"34","author":"Zakharia","year":"2016","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301\/KEYNOTE-252 study","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1042\/ETLS20170142","article-title":"The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy","volume":"1","author":"Marincola","year":"2017","journal-title":"Emerg Top Life Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","article-title":"Immunological effects of BRAF+MEK inhibition","volume":"7","author":"Ascierto","year":"2018","journal-title":"Oncoimmunology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.4161\/onci.21940","article-title":"BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer","volume":"1","author":"Donia","year":"2012","journal-title":"Oncoimmunology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e22890","DOI":"10.4161\/onci.22890","article-title":"Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells","volume":"2","author":"Sapkota","year":"2013","journal-title":"Oncoimmunology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fimmu.2019.00990","article-title":"Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma","volume":"10","author":"Yu","year":"2019","journal-title":"Front Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2018.11.018","article-title":"Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma","volume":"442","author":"Brummer","year":"2019","journal-title":"Cancer Lett."},{"key":"B19","doi-asserted-by":"publisher","first-page":"178646917691938","DOI":"10.1177\/1178646917691938","article-title":"Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects","volume":"10","author":"Badawy","year":"2017","journal-title":"Int J Tryptophan Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/j.1460-9568.2007.05838.x","article-title":"Altered kynurenine metabolism correlates with infarct volume in stroke","volume":"26","author":"Darlington","year":"2007","journal-title":"Eur J Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4137\/IJTR.S11789","article-title":"Characterization of the kynurenine pathway and quinolinic Acid production in macaque macrophages","volume":"6","author":"Lim","year":"2013","journal-title":"Int J Tryptophan Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","article-title":"Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia","volume":"37","author":"Sathyasaikumar","year":"2011","journal-title":"Schizophr Bull."},{"key":"B23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s007020050149","article-title":"Kynurenine metabolism in Alzheimer's disease","volume":"106","author":"Baran","year":"1999","journal-title":"J Neural Transm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3945\/jn.113.189738","article-title":"Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients","volume":"144","author":"Midttun","year":"2014","journal-title":"J Nutr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"154148","DOI":"10.1016\/j.cyto.2017.09.004","article-title":"The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis","volume":"122","author":"Baumgartner","year":"2019","journal-title":"Cytokine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.gene.2007.04.010","article-title":"Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice","volume":"396","author":"Ball","year":"2007","journal-title":"Gene."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1158\/0008-5472.CAN-07-1872","article-title":"Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan","volume":"67","author":"Metz","year":"2007","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00239-007-9049-1","article-title":"Evolution of vertebrate indoleamine 2,3-dioxygenases","volume":"65","author":"Yuasa","year":"2007","journal-title":"J Mol Evol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00018-009-0166-4","article-title":"Structure, expression, and function of kynurenine aminotransferases in human and rodent brains","volume":"67","author":"Han","year":"2009","journal-title":"Cell Mol Life Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12039","article-title":"Structural basis of kynurenine 3-monooxygenase inhibition","volume":"496","author":"Amaral","year":"2013","journal-title":"Nature."},{"key":"B31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat Rev Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1158\/1078-0432.CCR-07-4144","article-title":"Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival","volume":"14","author":"Ino","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.lungcan.2009.05.001","article-title":"Increased serum kynurenine\/tryptophan ratio correlates with disease progression in lung cancer","volume":"67","author":"Suzuki","year":"2010","journal-title":"Lung Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1158\/1078-0432.CCR-08-0991","article-title":"Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model","volume":"14","author":"Yoshida","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/em.20588","article-title":"Possible roles of excess tryptophan metabolites in cancer","volume":"52","author":"Chung","year":"2011","journal-title":"Environ Mol Mutagen."},{"key":"B36","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2967\/jnumed.108.058776","article-title":"Quantification of tryptophan transport and metabolism in lung tumors using PET","volume":"50","author":"Juh\u00e1sz","year":"2009","journal-title":"J Nucl Med."},{"key":"B37","first-page":"21","article-title":"Tryptophan and its metabolites in patients with oral squamous cell carcinoma: preliminary study","volume":"51","author":"Tankiewicz","year":"2006","journal-title":"Adv Med Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.21873\/anticanres.11551","article-title":"The Kynurenine Pathway: a primary resistance mechanism in patients with glioblastoma","volume":"37","author":"Sordillo","year":"2017","journal-title":"Anticancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat Rev Drug Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/hsz-2015-0173","article-title":"Melanocytes are more responsive to IFN-\u03b3 and produce higher amounts of kynurenine than melanoma cells","volume":"397","author":"Clara","year":"2016","journal-title":"Biol Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"14152","DOI":"10.1073\/pnas.1119744109","article-title":"Tumor suppressor TSC1 is critical for T-cell anergy","volume":"109","author":"Xie","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.4161\/onci.21716","article-title":"IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan","volume":"1","author":"Metz","year":"2012","journal-title":"Oncoimmunology."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3389\/fimmu.2018.01051","article-title":"Expression of indoleamine 2,3-dioxygenase induced by IFN-gamma and TNF-alpha as potential biomarker of prostate cancer progression","volume":"9","author":"Banzola","year":"2018","journal-title":"Front Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ejca.2011.09.007","article-title":"Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients","volume":"48","author":"Speeckaert","year":"2012","journal-title":"Eur J Cancer."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.18632\/oncotarget.6467","article-title":"Understanding the role of the kynurenine pathway in human breast cancer immunobiology","volume":"7","author":"Heng","year":"2016","journal-title":"Oncotarget."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e3029","DOI":"10.1038\/cddis.2017.406","article-title":"Silencing FLI or targeting CD13\/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells","volume":"8","author":"Azimi","year":"2017","journal-title":"Cell Death Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS ONE."},{"key":"B49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcdb.2016.01.012","article-title":"Evaluating network inference methods in terms of their ability to preserve the topology and complexity of genetic networks","volume":"51","author":"Kiani","year":"2016","journal-title":"Semin Cell Dev Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol Cell Proteomics."},{"key":"B51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion","volume":"186","author":"Coffelt","year":"2011","journal-title":"J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-015-0096-7","article-title":"Inhibition of the angiopoietin\/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack","volume":"3","author":"Grenga","year":"2015","journal-title":"J Immunother Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.4049\/jimmunol.1701219","article-title":"Dysregulated Th1 immune and vascular responses in scrub typhus pathogenesis","volume":"200","author":"Soong","year":"2018","journal-title":"J Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","article-title":"GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase","volume":"22","author":"Munn","year":"2005","journal-title":"Immunity."},{"key":"B56","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/imm.12502","article-title":"Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells","volume":"146","author":"Eleftheriadis","year":"2015","journal-title":"Immunology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","article-title":"Inhibition of T cell proliferation by macrophage tryptophan catabolism","volume":"189","author":"Munn","year":"1999","journal-title":"J Exp Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/0008-5472.CAN-17-2995","article-title":"IDO immune status after chemoradiation may predict survival in lung cancer patients","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.jocn.2015.06.018","article-title":"The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy","volume":"22","author":"Zhai","year":"2015","journal-title":"J Clin Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.biopsych.2016.12.011","article-title":"Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders","volume":"82","author":"Erhardt","year":"2017","journal-title":"Biol Psychiatry."},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12640-017-9714-0","article-title":"Correlations of kynurenic acid, 3-hydroxykynurenine, sIL-2R, IFN-alpha, and IL-4 with clinical symptoms during acute relapse of schizophrenia","volume":"32","author":"Szymona","year":"2017","journal-title":"Neurotox Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.jpsychires.2013.08.008","article-title":"Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine","volume":"47","author":"Johansson","year":"2013","journal-title":"J Psychiatr Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"11239","DOI":"10.1073\/pnas.89.23.11239","article-title":"Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew","volume":"89","author":"Freeman","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B64","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.bcp.2011.06.013","article-title":"Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10","volume":"82","author":"Hertenstein","year":"2011","journal-title":"Biochem Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1182\/blood-2008-02-137414","article-title":"Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP","volume":"112","author":"Mazzucchelli","year":"2008","journal-title":"Blood."},{"key":"B66","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.190.7.995","article-title":"An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation","volume":"190","author":"Asseman","year":"1999","journal-title":"J Exp Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/s41598-019-48635-x","article-title":"Exhaustion of CD4+ T-cells mediated by the kynurenine pathway in melanoma","volume":"9","author":"Rad Pour","year":"2019","journal-title":"Sci Rep."},{"key":"B68","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1471-4159.2004.02191.x","article-title":"Mitogen-activated protein kinase\/extracellular signal-regulated kinase attenuates 3-hydroxykynurenine-induced neuronal cell death","volume":"88","author":"Lee","year":"2004","journal-title":"J Neurochem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/jid.2013.303","article-title":"Kynurenine increases matrix metalloproteinase-1 and\u22123 expression in cultured dermal fibroblasts and improves scarring in vivo","volume":"134","author":"Li","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4049\/jimmunol.1302616","article-title":"Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment","volume":"192","author":"Wilmott","year":"2014","journal-title":"J Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/j.1471-4159.2008.05241.x","article-title":"Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity","volume":"105","author":"Owe-Young","year":"2008","journal-title":"J Neurochem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00702-011-0681-y","article-title":"The kynurenine system and immunoregulation","volume":"119","author":"M\u00e1ndi","year":"2012","journal-title":"J Neural Transm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.cdd.4401073","article-title":"T cell apoptosis by tryptophan catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T15:04:39Z","timestamp":1581001479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":73,"alternative-id":["10.3389\/fonc.2020.00051"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00051","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"article-number":"51"}}